The Valuation and Strategic Role of Amgen as an Anchor Stock in the Biopharmaceutical Industry Under Market Volatility

Abstract

The research implements a scientific method for choosing anchor stocks and determining their value in the U.S. biopharmaceutical industry through a case study of Amgen. The research evaluates Amgen’s intrinsic value by analyzing three financial metrics including NTM P/E ratio and PEG ratio and GP/A ratio and performs a peer analysis with Gilead Sciences, Biogen and Regeneron to assess competitive advantages and disadvantages. The analysis reveals that Amgen provides diversified therapeutic exposure and stable cash flows and consistent dividends which makes it a defensive growth investment that matches the Growth at a Reasonable Price (GARP) profile. The company faces three main challenges which include biosimilar competition, margin pressures and regulatory changes from the Inflation Reduction Act, and increased R&D expenses. The valuation analysis indicates possible moderate price appreciation which depends on successful late-stage pipeline development and margin improvement. The research establishes theoretical evidence for selecting anchor stocks during market volatility while offering practical methods to build investment portfolios that unite stability with growth potential in biopharmaceuticals.